MALVERN, PA--(Marketwire - October 21, 2008) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL)
today announced that executive management will participate in the
Oppenheimer Healthcare Conference to be held November 3 - 4 at The
Waldorf-Astoria in New York City. Mr. Armando Anido, Chief Executive
Officer, is scheduled to present an overview of the Company and its product
pipeline at 11:20 a.m. EST on Monday, November 3, 2008.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has five
projects in clinical development. XIAFLEX™ (clostridial collagenase for
injection), formerly referred to as AA4500, is in phase III of development
for the treatment of Dupuytren's contracture and is in phase II of
development for the treatment of Peyronie's disease and Frozen Shoulder
syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product
candidate for the treatment of overactive bladder (AA4010) is in phase I of
development. The Company is currently seeking a partner to further develop
this product candidate. Auxilium also has one pain product using its
transmucosal film delivery system in phase I of development. Auxilium has
rights to seven additional pain products and products for hormone
replacement and urologic disease using its transmucosal film delivery
system. Auxilium also has options to all indications using XIAFLEX for
non-topical formulations. For additional information, visit
http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the 19th Annual Oppenheimer
Healthcare Conference, and the Company's products in development for
Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome,
overactive bladder, pain, hormone replacement and urologic disease. All
statements other than statements of historical facts contained in this
release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including general
financial, economic, regulatory and political conditions affecting the
biotechnology and pharmaceutical industries and those discussed in the
Company's Annual Report on Form 10-K for the year ended December 31, 2007
under the heading "Risk Factors," which is on file with the Securities and
Exchange Commission (the "SEC") and may be accessed electronically by means
of the SEC's home page on the Internet at http://www.sec.gov or by means of
the Company's home page on the Internet at http://www.auxilium.com under
the heading "Investor Relations -- SEC Filings." There may be additional
risks that the Company does not presently know or that the Company
currently believes are immaterial which could also cause actual results to
differ from those contained in the forward-looking statements. Given these
risks and uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such factors
or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.
Contact Information: For More Information, Contact:
James E. Fickenscher
CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
William Q. Sargent, Jr.
V.P., IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900